利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.032 秒)

    OXIME COMPOUNDS AND THE USE THEREOF
    2.
    发明申请
    OXIME COMPOUNDS AND THE USE THEREOF 审中-公开
    OXIME化合物及其用途

    公开(公告)号：US20090298878A1

    公开(公告)日：2009-12-03

    申请号：US12373328

    申请日：2007-07-12

    申请人： Akira Matsumura ,  Hidenori Mikamiyama ,  Naoki Tsuno ,  Donald J. Kyle ,  Bin Shao ,  Jiangchao Yao

    发明人： Akira Matsumura ,  Hidenori Mikamiyama ,  Naoki Tsuno ,  Donald J. Kyle ,  Bin Shao ,  Jiangchao Yao

    IPC分类号： A61K31/445 ,  C07D211/98 ,  G01N23/00 ,  C07D401/12

    CPC分类号： C07D211/72 ,  C07D211/96 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

    摘要： The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CR3R4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R3 and R4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is 0, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及式（I）的肟化合物及其药学上可接受的盐，前药或溶剂化物，其中X是氢，任选取代的芳基，任选取代的杂芳基等; Y是CO，SO2，CR3R4等; Z是任选取代的低级烷基，任选取代的芳基等; W是任选取代的低级亚烷基或任选取代的低级亚烯基，R 3和R 4各自独立地是氢，低级烷基等; p是0,1或2，q是0,1或2.本发明还涉及使用式I化合物来治疗，预防或改善对阻断钙通道有响应的病症，特别是N型 钙通道。 本发明的化合物特别适用于治疗疼痛。

    Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
    3.
    发明授权
    Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators 有权
    取代的喹喔啉型桥接哌啶化合物作为ORL-1调节剂

    公开(公告)号：US08476271B2

    公开(公告)日：2013-07-02

    申请号：US13010632

    申请日：2011-01-20

    申请人： Naoki Tsuno ,  Jiangchao Yao

    发明人： Naoki Tsuno ,  Jiangchao Yao

    IPC分类号： A61K31/495

    CPC分类号： C07D471/08 ,  C07D403/04 ,  C07D451/14

    摘要： Compounds of Formula (I): where R1, R2, R5, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a “Substituted-Quinoxaline-Type Bridged-Piperidine Compound”), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

    摘要翻译： 式（I）的化合物：其中R 1，R 2，R 5，a和b在此公开，及其药学上可接受的衍生物（“取代的喹喔啉型桥连哌啶化合物”），包含有效量的取代 - 喹喔啉型桥连哌啶化合物，以及治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量的取代的喹喔啉型桥连哌啶化合物。

    Benzenesulfonamide compounds and the use thereof
    6.
    发明授权
    Benzenesulfonamide compounds and the use thereof 有权
    苯磺酰胺化合物及其用途

    公开(公告)号：US08937181B2

    公开(公告)日：2015-01-20

    申请号：US12296788

    申请日：2007-04-13

    申请人： Akira Matsumura ,  Hidenori Mikamiyama ,  Bin Shao ,  Naoki Tsuno ,  Jiangchao Yao

    发明人： Akira Matsumura ,  Hidenori Mikamiyama ,  Bin Shao ,  Naoki Tsuno ,  Jiangchao Yao

    IPC分类号： C07D211/58 ,  A61K31/4545 ,  A61K31/4468

    CPC分类号： C07D211/58 ,  A61K31/4468 ,  A61K31/4545

    摘要： The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及式（I）的氮杂环丁烷基，吡咯烷基，哌啶基和六氢氮杂卟啉化合物及其药学上可接受的盐，前药或溶剂化物，其中R1-R3，Z，p和q如说明书所述定义。 本发明还涉及使用式（I）化合物来治疗，预防或改善对阻断钙通道，特别是N型钙通道的病症。 本发明的化合物特别适用于治疗疼痛。

    OXYIMINO COMPOUNDS AND THE USE THEREOF
    8.
    发明申请
    OXYIMINO COMPOUNDS AND THE USE THEREOF 有权
    OXYIMINO化合物及其用途

    公开(公告)号：US20100240703A1

    公开(公告)日：2010-09-23

    申请号：US12602441

    申请日：2008-05-30

    申请人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    IPC分类号： A61K31/445 ,  C07D211/96 ,  A61P29/00 ,  A61P25/00 ,  A61P9/06 ,  A61P9/12 ,  G01N33/53

    CPC分类号： C07D211/96

    摘要： The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及（式I）的氧亚氨基化合物及其药学上可接受的盐，前药和溶剂化物，其中：Y是CO或SOm; Z是氢，每个任选取代的低级烷基，低级烯基，芳基，杂环基等.R 1和R 2各自独立地为氢，各自为任选取代的低级烷基，低级烯基，环烷基，芳基，杂环基等，各X独立地为= 任选取代的低级烷基，氰基，硝基等，m为1或2，p为O，1或2，q为O或1.本发明还涉及式I的用途化合物，以治疗，预防或改善 对钙通道阻断，特别是N型钙通道的阻滞作用。 本发明的化合物特别适用于治疗疼痛。

    Oxyimino compounds and the use thereof
    9.
    发明授权
    Oxyimino compounds and the use thereof 有权
    氧亚氨基化合物及其用途

    公开(公告)号：US08563732B2

    公开(公告)日：2013-10-22

    申请号：US12602441

    申请日：2008-05-30

    申请人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Hidenori Mikamiyama ,  Naoki Tsuno

    IPC分类号： A61K31/44 ,  C07D211/00

    CPC分类号： C07D211/96

    摘要： The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译： 本发明涉及（式I）的氧亚氨基化合物及其药学上可接受的盐，前药和溶剂化物，其中：Y是CO或SOm; Z是氢，每个任选取代的低级烷基，低级烯基，芳基，杂环基等.R 1和R 2各自独立地为氢，各自为任意取代的低级烷基，低级烯基，环烷基，芳基，杂环基等，各X独立地为= 任选取代的低级烷基，氰基，硝基等，m为1或2，p为O，1或2，q为O或1.本发明还涉及式I的用途化合物，以治疗，预防或改善 对钙通道阻断，特别是N型钙通道的阻滞作用。 本发明的化合物特别适用于治疗疼痛。

    Nitrogen-containing heterocycle derivatives substituted with cyclic group
    10.
    发明授权
    Nitrogen-containing heterocycle derivatives substituted with cyclic group 失效
    用环状基团取代的含氮杂环衍生物

    公开(公告)号：US07935706B2

    公开(公告)日：2011-05-03

    申请号：US12278412

    申请日：2007-02-21

    申请人： Moriyasu Masui ,  Makoto Adachi ,  Hidenori Mikamiyama ,  Akira Matsumura ,  Naoki Tsuno

    发明人： Moriyasu Masui ,  Makoto Adachi ,  Hidenori Mikamiyama ,  Akira Matsumura ,  Naoki Tsuno

    IPC分类号： A61K31/497

    CPC分类号： C07D209/08 ,  C07D209/34 ,  C07D215/38 ,  C07D235/08 ,  C07D235/26 ,  C07D249/18 ,  C07D263/58 ,  C07D277/68 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

    摘要： It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

    摘要翻译： 发现由式（I）表示的含氮杂环衍生物特异性结合NR1 / NR2B的受体，并用作NR2B受体拮抗剂。 由下式表示的化合物：其中Z为N或CR1，A1为任选取代的含氮芳族单环基团，任选取代的含氮芳族稠合环基等，A2为芳族烃环基或 芳族杂环基，各自任选具有取代基，R 1，R 2，R a，R b，R c和R d各自独立地为氢，羟基等，w为2或3，t为1或2，X为 - （CR 3 R 4）m - ，-CO（CR 3 R 4）n - ， - CONR 5（CR 3 R 4）n - 等，m为1〜4的整数，n为0〜4的整数，R 3和R 4各自独立地为氢，卤素，羟基等 R5为氢或低级烷基，或其药学上可接受的盐或溶剂合物。